Pyruvate secreted from patient‐derived cancer‐associated fibroblasts supports survival of primary lymphoma cells
暂无分享,去创建一个
T. Aoki | A. Tomita | H. Kiyoi | F. Hayakawa | M. Tsunoda | Chisako Iriyama | K. Shimada | A. Sakamoto | Shunsuke Kunou | S. Nakamura | S. Nakamura
[1] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[2] P. Khong,et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. , 2017, Blood.
[3] Ya'an Kang,et al. Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism , 2017, Oncology reports.
[4] T. Aoki,et al. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism , 2016, Oncotarget.
[5] T. Funatsu,et al. Live-cell single-molecule imaging of the cytokine receptor MPL for analysis of dynamic dimerization. , 2016, Journal of molecular cell biology.
[6] M. Shipp,et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Naoe,et al. SPIB is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the PI3K‐AKT pathway , 2016, Cancer science.
[8] R. Kalluri. The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.
[9] R. Hill,et al. CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS , 2016, Oncogene.
[10] M. Gasparetto,et al. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. , 2016, Cell stem cell.
[11] J. Locasale,et al. The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.
[12] T. Naoe,et al. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells , 2015, Scientific Reports.
[13] L. Solt,et al. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. , 2015, Cancer cell.
[14] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[15] John M. Asara,et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.
[16] R. Gascoyne,et al. The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.
[17] E. Giannoni,et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. , 2012, Cancer research.
[18] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Naoe,et al. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. , 2012, Experimental hematology.
[20] C. Croce,et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukemia , 2012, Nature Cell Biology.
[21] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[22] F. Sotgia,et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution , 2010, Cell cycle.
[23] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Fortina,et al. The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma , 2009, Cell cycle.
[25] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[26] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[27] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[28] T. Hara,et al. Lymph Node Fibroblastic Reticular Cells Construct the Stromal Reticulum via Contact with Lymphocytes , 2004, The Journal of experimental medicine.
[29] M. Tomita,et al. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. , 2003, Journal of proteome research.
[30] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[31] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[32] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[33] T. Tlsty,et al. Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated Human Prostatic Epithelium , 2022 .